Indications
Abetis tablets are prescribed to manage high blood pressure. This medication may be administered as standalone therapy or alongside other blood pressure-lowering treatments.
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Pharmacology
Olmesartan, the active component, selectively inhibits angiotensin II binding at vascular AT₁ receptors. This hormone normally elevates blood pressure through vasoconstriction and aldosterone release. By blocking AT₁ receptors (with 12,500-fold selectivity over AT₂ receptors), olmesartan reduces blood pressure without inhibiting ACE or affecting bradykinin pathways. Increased angiotensin II levels from renin feedback do not counteract its antihypertensive effect.

Dosage & Administration

• Starting dose: 20 mg once daily

• May increase to 40 mg after 2 weeks if needed

• Maximum efficacy achieved at 40 mg; higher doses show no added benefit

• Twice-daily dosing provides no advantage over once-daily regimen

• No initial adjustment required for elderly or moderate-severe renal/hepatic impairment

• Use lower starting dose under medical supervision in volume-depleted patients (e.g., diuretic users)

• May be taken with/without food

• Pediatric safety not established
  রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন

Interaction

• No significant interactions with digoxin, warfarin, or antacids

• Minimal cytochrome P450 involvement reduces metabolic interaction risks

• NSAIDs/COX-2 inhibitors may:

  • Worsen renal function (especially in elderly/volume-depleted patients)

  • Reduce antihypertensive efficacy

  • Require periodic renal monitoring during co-administration

Contraindications
Hypersensitivity to olmesartan medoxomil or tablet components.

Side Effects

• Most common: Dizziness (3% vs placebo 1%)

• Other reported effects (frequency ≥1%, comparable to placebo): Back pain, bronchitis, elevated CPK, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, flu-like symptoms, pharyngitis, rhinitis, sinusitis

• Discontinuation rate: 2.4% (vs 2.7% controls)

• Cough incidence: 0.9% (placebo 0.7%)

Pregnancy & Lactation

• Discontinue immediately upon pregnancy detection due to fetal injury/death risk in later trimesters

• Breastfeeding not recommended (olmesartan detected in rodent milk; human excretion unknown)

Precautions & Warnings

• May impair renal function in renin-angiotensin-aldosterone system-dependent patients (e.g., severe heart failure)

• Monitor for oliguria, azotemia, or acute renal failure

Overdose Effects

• Primary symptoms: Hypotension, tachycardia

• Potential bradycardia with vagal stimulation

• Management: Gastric lavage, cardiovascular support, fluid/renal monitoring

Therapeutic Class
Angiotensin II receptor blocker

Storage Conditions
Below 30°C in dry, light-protected environment. Keep away from children.

Chemical Structure

• Molecular Formula: C₂₉H₃₀N₆O₆

• Structure: Olmesartan medoxomil